Send me a link:

*Text messaging rates may apply.

 Dow Up0.17% Nasdaq Up0.44%

Bio-Path Holdings, Inc. (BPTH)

2.79 Up 0.12(4.49%) Jul 11, 4:00PM EDT
ProfileGet Profile for:
Bio-Path Holdings, Inc.
2626 South Loop
Suite 180
Houston, TX 77054
United States - Map
Phone: 832-971-6616

Index Membership:N/A
Industry:Drug Delivery
Full Time Employees:2

Business Summary 

Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase I study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Bio-Path Holdings, Inc.

Key Executives 
Mr. Peter H. Nielsen MBA, 64
Co-Founder, Chairman, Chief Exec. Officer, Pres, Chief Financial Officer, Chief Accounting Officer and Treasurer
Dr. Douglas P. Morris , 58
Co-Founder and Director
Dr. Ulrich W. Mueller Ph.D., 47
Chief Operating Officer
Dr. Alan MacKenzie Ph.D.,
Dr. Thomas A. Walker Ph.D.,
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders